Author Manuscript Published OnlineFirst on May 26, 2015; DOI: 10.1158/2326-6066.CIR-14-0244 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

5HVLVWDQFHWRDQWLDQJLRJHQLFWKHUDS\LVDVVRFLDWHGZLWKDQLPPXQRVXSSUHVVLYH WXPRUPLFURHQYLURQPHQWLQPHWDVWDWLFUHQDOFHOOFDUFLQRPD ;LDQ'H /LX $QK +RDQJ /LMXQ =KRX 6DUDWKL .DOUD $OSHU

Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.

Renal cell carcinoma (RCC) is an immunogenic and proangiogenic cancer, and antiangiogenic therapy is the current mainstay of treatment. Patients with ...
2MB Sizes 0 Downloads 9 Views
Download PDF

Recommend Documents

Antiangiogenic therapy in metastatic renal cell carcinoma: more promises and more challenges for imaging.
Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
Systemic therapy in metastatic renal cell carcinoma.
Sequential Therapy in Metastatic Renal Cell Carcinoma.
Deferred systemic therapy in patients with metastatic renal cell carcinoma.
Genetic mutations associated with metastatic clear cell renal cell carcinoma.
Combination therapy for metastatic renal cell carcinoma.
Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma.
Linear IgA bullous dermatosis associated with metastatic renal cell carcinoma.
GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance.

Follow Us

Copyright © 2024 D.DOCKSCI.COM. All rights reserved. | Design by w3layouts